NO951307L - Terapeutiske anti-HIV oligonukleotider - Google Patents
Terapeutiske anti-HIV oligonukleotiderInfo
- Publication number
- NO951307L NO951307L NO951307A NO951307A NO951307L NO 951307 L NO951307 L NO 951307L NO 951307 A NO951307 A NO 951307A NO 951307 A NO951307 A NO 951307A NO 951307 L NO951307 L NO 951307L
- Authority
- NO
- Norway
- Prior art keywords
- oligonucleotides
- hiv
- therapeutic anti
- disclosed
- nucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95813592A | 1992-10-05 | 1992-10-05 | |
PCT/US1993/009392 WO1994008004A1 (fr) | 1992-10-05 | 1993-10-04 | Oligonucleotides therapeutiques antiviraux anti-vih et produit pharmaceutique |
Publications (2)
Publication Number | Publication Date |
---|---|
NO951307D0 NO951307D0 (no) | 1995-04-04 |
NO951307L true NO951307L (no) | 1995-06-01 |
Family
ID=25500631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO951307A NO951307L (no) | 1992-10-05 | 1995-04-04 | Terapeutiske anti-HIV oligonukleotider |
Country Status (19)
Country | Link |
---|---|
US (1) | US5684147A (fr) |
EP (1) | EP0664833B1 (fr) |
JP (1) | JPH08504570A (fr) |
KR (1) | KR950704482A (fr) |
AT (1) | ATE146819T1 (fr) |
AU (1) | AU678415B2 (fr) |
BR (1) | BR9307191A (fr) |
CA (1) | CA2146364A1 (fr) |
CZ (1) | CZ85495A3 (fr) |
DE (1) | DE69306969T2 (fr) |
DK (1) | DK0664833T3 (fr) |
ES (1) | ES2096343T3 (fr) |
FI (1) | FI951600A (fr) |
GR (1) | GR3022315T3 (fr) |
HU (1) | HUT72400A (fr) |
NO (1) | NO951307L (fr) |
NZ (1) | NZ257434A (fr) |
PL (1) | PL308261A1 (fr) |
WO (1) | WO1994008004A1 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5733781A (en) * | 1994-07-19 | 1998-03-31 | Gen-Probe Incorporated | Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
EP1584681A3 (fr) * | 1997-07-10 | 2005-11-09 | GeneSense Technologies Inc. | Sequences oligonucleotidiques antisens servant d'inhibiteurs de micro-organismes |
US6610539B1 (en) * | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
ATE317432T1 (de) | 1997-08-19 | 2006-02-15 | Idera Pharmaceuticals Inc | Hiv-spezifische oligonukleotide und verfahren zu deren verwendung |
EP1077722B1 (fr) | 1998-05-22 | 2006-08-09 | Ottawa Health Research Institute | Methodes et produits permettant d'induire une immunite au niveau des muqueuses |
WO2000027795A1 (fr) | 1998-11-12 | 2000-05-18 | Invitrogen Corporation | Reactifs de transfection |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
DE60041489D1 (de) * | 1999-07-09 | 2009-03-19 | Gen Probe Inc | Nachweis von hiv-1 durch amplifizierung von nukleinsäuren |
CA2396677A1 (fr) * | 1999-12-23 | 2001-06-28 | The Board Of Regents Of The University Of Texas System | Inhibition de proteases cellulaires |
DE60131430T2 (de) * | 2000-01-14 | 2008-10-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
US6582920B2 (en) * | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
JP2002125687A (ja) * | 2000-10-30 | 2002-05-08 | Tosoh Corp | Hiv−1検出のためのオリゴヌクレオチドおよび検出法 |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
EP1446162B1 (fr) | 2001-08-17 | 2008-10-15 | Coley Pharmaceutical GmbH | Oligonucleotides immunostimulateurs a motif combine possedant une activite accrue |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
JP2006515277A (ja) | 2002-10-29 | 2006-05-25 | コーリー ファーマシューティカル グループ, リミテッド | C型肝炎ウィルス感染の処置および予防に関する方法および製品 |
JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
EP1627563A1 (fr) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Moyens et méthodes de préparation de cellules stabilisées |
EP1647595A1 (fr) * | 2004-10-15 | 2006-04-19 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Acides nucléiques contre des virus, en particulier contre le VIH |
US8399423B2 (en) * | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
US8383364B2 (en) | 2005-11-17 | 2013-02-26 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
USRE49583E1 (en) | 2005-11-17 | 2023-07-18 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
WO2007067032A1 (fr) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Moyen et methodes permettant d'influencer la stabilite de cellules |
ES2444465T5 (es) | 2005-12-09 | 2023-11-30 | Academisch Medisch Centrum Bij De Univ Van Amsterdam | Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos |
CA2768207C (fr) | 2009-07-15 | 2019-12-03 | Aimm Therapeutics B.V. | Moyens et procedes de production d'anticorps a haute affinite |
EP2550362B1 (fr) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Glycoprotéines du cmv et vecteurs recombinés |
ES2626671T3 (es) | 2010-12-02 | 2017-07-25 | Aimm Therapeutics B.V. | Medios y métodos para producir anticuerpos de alta afinidad |
CA2832109C (fr) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Glycoproteines de cmv et vecteurs recombinants cmv |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2679596B1 (fr) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | Variante de la protéine env du VIH-1 |
WO2015027334A1 (fr) * | 2013-08-26 | 2015-03-05 | The Royal Institution For The Advancement Of Learning / Mcgill University | Agents à base de petit arn antisens ciblant le cadre de lecture ouvert gag de l'arn du vih-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (fr) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Trimères de glycoprotéines d'enveloppe du vih -1 soluble |
AU2015211480B2 (en) | 2014-01-31 | 2020-05-14 | Kling Biotherapeutics B.V. | Means and methods for producing stable antibodies |
EP3169310A1 (fr) | 2014-07-15 | 2017-05-24 | Life Technologies Corporation | Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules |
EP3069730A3 (fr) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
EP3072901A1 (fr) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68929343T2 (de) * | 1988-02-16 | 2002-09-12 | Greatbatch Gen-Aid, Ltd. | Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen |
WO1989008146A1 (fr) * | 1988-02-26 | 1989-09-08 | Worcester Foundation For Experimental Biology | Inhibition du htlv-iii par des oligonucleotides exogenes |
-
1993
- 1993-10-04 AU AU54028/94A patent/AU678415B2/en not_active Ceased
- 1993-10-04 BR BR9307191A patent/BR9307191A/pt not_active Application Discontinuation
- 1993-10-04 JP JP6509354A patent/JPH08504570A/ja active Pending
- 1993-10-04 HU HU9500995A patent/HUT72400A/hu unknown
- 1993-10-04 EP EP93924289A patent/EP0664833B1/fr not_active Expired - Lifetime
- 1993-10-04 PL PL93308261A patent/PL308261A1/xx unknown
- 1993-10-04 KR KR1019950701317A patent/KR950704482A/ko not_active Application Discontinuation
- 1993-10-04 CA CA002146364A patent/CA2146364A1/fr not_active Abandoned
- 1993-10-04 ES ES93924289T patent/ES2096343T3/es not_active Expired - Lifetime
- 1993-10-04 DK DK93924289.7T patent/DK0664833T3/da active
- 1993-10-04 WO PCT/US1993/009392 patent/WO1994008004A1/fr not_active Application Discontinuation
- 1993-10-04 AT AT93924289T patent/ATE146819T1/de not_active IP Right Cessation
- 1993-10-04 CZ CZ95854A patent/CZ85495A3/cs unknown
- 1993-10-04 DE DE69306969T patent/DE69306969T2/de not_active Expired - Fee Related
- 1993-10-04 NZ NZ257434A patent/NZ257434A/en unknown
-
1994
- 1994-10-07 US US08/319,823 patent/US5684147A/en not_active Expired - Lifetime
-
1995
- 1995-04-04 FI FI951600A patent/FI951600A/fi not_active Application Discontinuation
- 1995-04-04 NO NO951307A patent/NO951307L/no unknown
-
1997
- 1997-01-17 GR GR960403507T patent/GR3022315T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
HU9500995D0 (en) | 1995-06-28 |
US5684147A (en) | 1997-11-04 |
KR950704482A (ko) | 1995-11-20 |
PL308261A1 (en) | 1995-07-24 |
ES2096343T3 (es) | 1997-03-01 |
EP0664833B1 (fr) | 1996-12-27 |
EP0664833A1 (fr) | 1995-08-02 |
ATE146819T1 (de) | 1997-01-15 |
DE69306969D1 (de) | 1997-02-06 |
HUT72400A (en) | 1996-04-29 |
CA2146364A1 (fr) | 1994-04-14 |
AU678415B2 (en) | 1997-05-29 |
DE69306969T2 (de) | 1997-05-07 |
FI951600A0 (fi) | 1995-04-04 |
NZ257434A (en) | 1997-01-29 |
CZ85495A3 (en) | 1996-03-13 |
WO1994008004A1 (fr) | 1994-04-14 |
DK0664833T3 (da) | 1997-04-14 |
BR9307191A (pt) | 1999-03-30 |
FI951600A (fi) | 1995-05-10 |
GR3022315T3 (en) | 1997-04-30 |
AU5402894A (en) | 1994-04-26 |
NO951307D0 (no) | 1995-04-04 |
JPH08504570A (ja) | 1996-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO951307L (no) | Terapeutiske anti-HIV oligonukleotider | |
AU8771398A (en) | Novel hiv-specific synthetic oligonucleotides and methods of their use | |
ATE181960T1 (de) | Gegensinnige hemmer des humanen immunmangel virus (hiv) | |
ATE202383T1 (de) | Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten | |
CA2165821A1 (fr) | Oligonucleotides antisens et utilisation therapeutique de ceux-ci dans l'infection par le virus de l'immunodeficience humaine | |
WO1994024144A3 (fr) | Formation a helice triple et double a l'aide d'oligomeres contenant des purines modifiees | |
DK0677056T3 (da) | Oligonukleotid-alkylphosphonater og -alkylphosphonothioater | |
CA2220433A1 (fr) | Inhibiteur de l'activite de il-6 | |
FI946201A0 (fi) | Itsestabiloidut oligonukleotidit terapeuttisina aineina | |
DE68925278D1 (de) | Hemmung von htlv-iii durch exogene oligonukleotide | |
NO971493D0 (no) | Virusmateriale og nukleotidfragmenter som er forbundet med multippel sklerose, og som kan anvendes til diagnostiske, preventive og terapeutiske formål | |
HUP0103465A2 (hu) | A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok | |
KR960704034A (ko) | 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens) | |
EP0503002A4 (en) | Antisense oligonucleotide inhibition of papillomavirus | |
AP1674A (en) | The genome of the HIV-1 inter-subtype (C/B') and use thereof. | |
ATE160354T1 (de) | Oligonukleotide mit anti-cytomegalovirus wirkung | |
MX9707674A (es) | Uso de una linfosina que suprime el virus de inmunodeficiencia (isl) para inhibir la replicacion de los virus, en particular de los retrovirus. | |
TH23381A (th) | โอลิโกนิวคลีโอไทด์สำหรับยับยั้งการแสดงลักษณะของไอโซพรีนิลโปรตีนทรานสเฟอเรส |